Timing of HPV Infection Acquisition Linked to High-Grade CIN2+ in England
Overview
This study modeled the age distribution of causal HPV infection leading to CIN2+ diagnosis in England using NHS screening data from 2007–2008. The findings indicate that the median age of causal HPV infection occurs several years before CIN2+ diagnosis, with most infections acquired in young adulthood prior to screening age.
Background
Human papillomavirus (HPV) is the primary cause of cervical intraepithelial neoplasia (CIN) and cervical cancer. In England, over 335,000 women were diagnosed with CIN3 and nearly 30,000 with cervical cancer between 2006 and 2020. HPV infection risk peaks shortly after sexual debut and declines with age, but persistent infections can lead to CIN2+ lesions. HPV vaccination and cervical screening programs are key prevention strategies, with vaccination introduced nationally in 2008 and screening offered from age 25 to 64 years.
Data Highlights
Parameter
Value/Source
Number of women diagnosed with CIN3 (2006–2020)
335,228
Number of women diagnosed with cervical cancer (2006–2020)
29,968
Screening age range
25–64 years
Screening interval
Every 3 years (25–49 years), every 5 years (50–64 years)
Model simulated cohort
1,000 women
Time from causal HPV infection to CIN2+ onset
Gamma distribution with 6-month minimum
Screening sensitivity (liquid-based cytology)
~80.1%
Percentage of CIN2+ cases before screening age
8%
Key Findings
The model estimated the age of causal HPV infection by shifting the observed age distribution of CIN2+ diagnosis earlier by an offset representing time from infection to diagnosis.
Approximately 8% of CIN2+ cases occur before the start of screening at age 25.
The time from causal HPV infection to CIN2+ onset was modeled using a gamma distribution with parameters based on clinical trial data.
The model assumes the shape of the causal HPV infection age distribution mirrors that of CIN2+ diagnosis but shifted earlier.
Screening data from 2007–2008 NHS CSP in England were used to calibrate the model, prior to widespread HPV vaccination impact.
The model does not differentiate by HPV genotype and assumes detection only occurs through screening within the eligible age range.
Clinical Implications
Understanding the timing of causal HPV infection relative to CIN2+ diagnosis underscores the importance of early HPV vaccination before sexual debut to prevent infection and subsequent cervical precancer. The data support continued cervical screening starting at age 25 to detect and manage CIN2+ lesions arising from infections acquired in young adulthood. These findings may inform vaccination catch-up policies and screening strategies to reduce cervical cancer burden.
Conclusion
This modeling study provides insight into the age distribution of causal HPV infections leading to CIN2+ in England, highlighting that infections typically occur years before diagnosis and screening. These results reinforce the critical role of early vaccination and timely screening in cervical cancer prevention.
References
NHS CSP England 2007–2008 -- Cervical Screening Data
VIVIANE and FUTURE I Trials -- Time from HPV Infection to CIN2+ Onset
Prabhu et al. 2021 -- Modeling Age of Causal HPV Infection
